** Citigroup starts coverage of Kymera Therapeutics' KYMR.O shares with "buy/high risk" rating and $52 PT, a ~48% upside to stock's last close
** Brokerage says company's targeted protein degradation technology offers "first-in-class" approaches in the treatment of various inflammatory and immunological diseases
** Company's atopic dermatitis drug KT-621 has shown "robust preclinical data" with potential to achieve "comparable or superior efficacy" to Regeneron REGN.O and Sanofi's SASY.PA Dupixent, Citigroup says
** Kymera's inflammatory skin disease drug KT-474 has shown promising data in clinical trials, particularly in hidradenitis suppurativa, where it demonstrated a "remarkable ~60% reduction in symptoms", positioning it as a potential "best-in-class" therapy - brokerage
** Brokerage estimates company's revenue to reach $1 bln by 2032, with each additional $500 bln in sales potentially adding $20 to the stock price
** Kymera's shares rose 58.7% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。